Popular weight loss medications Wegovy and Ozempic have been linked to a rare but serious eye condition known as ischemic optic neuropathy, often referred to as an 'eye stroke', according to a recent study.
Study Highlights Association
Researchers noted that Wegovy showed the highest association with ischemic optic neuropathy among semaglutide-based GLP-1 drugs analyzed in the study. The findings have raised concerns among healthcare professionals and patients using these medications for weight management or diabetes control.
Understanding Ischemic Optic Neuropathy
Ischemic optic neuropathy occurs when blood flow to the optic nerve is blocked, leading to sudden vision loss. This condition can be irreversible and requires immediate medical attention. While rare, the potential link to GLP-1 receptor agonists like semaglutide warrants further investigation.
Warning Signs to Watch For
Anoop M, an eye consultant at Bridge Health, shared important warning signs that people on weight-loss drugs must look out for. These include:
- Sudden vision loss or blurring in one eye
- Painless loss of vision
- Loss of peripheral vision
- Color vision changes
Patients experiencing any of these symptoms should seek immediate ophthalmologic evaluation.
Expert Recommendations
Healthcare providers are advised to discuss the potential risks with patients before prescribing semaglutide-based drugs. Regular eye examinations may be recommended for those on long-term therapy. The study emphasizes the need for balanced consideration of benefits and risks when using these medications.
The research adds to a growing body of evidence examining the side effects of GLP-1 agonists, which have gained popularity for their effectiveness in weight loss and glycemic control. However, the potential ocular complications highlight the importance of vigilant monitoring.
As the use of these drugs continues to rise, further studies are needed to fully understand the mechanisms behind the association and to identify patients who may be at higher risk.
